Document is current
Any future updates will be listed below
-
Authors
Evidente, Virgilio G. H. https://orcid.org/0000-0001-6341-6933
Chrones, Lambros
Revankar, Ratna
Doshi, Dilesh
Abler, Victor
Rashid, Nazia
-
Funding
Funding for this research was provided by:
ACADIA Pharmaceuticals
- License Information
-
More Information
Article History
Received: 18 September 2024
Accepted: 17 April 2025
First Online: 12 May 2025
Declarations
:
: Virgilio Evidente has received personal compensation for serving as a consultant or speaker for AbbVie, Amneal, Ipsen, Medtronic, Merz, Neurocrine, Revance, Sunovion, and Teva; and has received research support from AbbVie, Acadia, Aeon, Aptinyx, Cerevance, CND Life Sciences, Ipsen, IRLAB, Jazz Pharmaceuticals, Neuraly, Neurocrine, Pharma Two B, Revance, Scion Neurostim, and Theravance. Lambros Chrones is an employee of Acadia Pharmaceuticals. Ratna Revankar is a consultant for Acadia Pharmaceuticals. Dilesh Doshi is an employee of Acadia Pharmaceuticals. Victor Abler is an employee of Acadia Pharmaceuticals. Nazia Rashid is an employee of Acadia pharmaceuticals.
: This study was conducted in compliance with the Helsinki Declaration of 1964, International Council for Harmonisation Good Clinical Practice, and other applicable regulatory requirements. Protocols received written approval by relevant Institutional Review Boards prior to study initiation and all patients provided written informed consent prior to enrolling. All authors consent to the publication of this article.
